qxnews

This week's sponsor is FierceCustomSurveys.
	Survey \| mHealth and the Internet of Things in Clinical Trials Share your opinions towards mHealth and clinical trials for a chance to win! The first 10 qualified respondents will receive a $5 Amazon gift card. Complete the survey today!

Today's Rundown

Featured Story

Kite, analysts unfazed by Juno trial issues, say low-dose fludarabine safe

July 14, 2016 | By Ben Adams

Kite Pharma has said it has no concerns with its recently enrolled experimental CAR-T trial that is using a chemo drug now dropped by rival Juno after it associated a high-dose form of the treatment with four deaths.

This week's sponsor is FierceBiotech’s Drug Development Forum.
FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration. Register now

Novartis gains FDA panel thumbs up for Amgen Enbrel copy

Thursday, July 14, 2016

Another day, another unanimous FDA panel vote, this time recommending Novartis’ Enbrel (etanercept) biosimilar be approved across all of its U.S. licenses.

Merck to ax R&D staff while also boosting research site investment

Wednesday, July 13, 2016

Merck will be giving with one hand and taking away with the other as it confirms cuts across its discovery and early-stage R&D businesses, but said it will also be boosting investment in two research sites.

Flagship snaps up Merck CMO

Wednesday, July 13, 2016

Flagship Ventures has created a new spot for former Merck EVP and CMO Dr. Michael Rosenblatt, benefiting from the R&D reorg at the pharma. He is joining the venture firm as CMO.

Amgen partners with Daiichi on biosimilars after positive FDA panel

Thursday, July 14, 2016

An FDA panel gave Amgen a thumbs up earlier this week for its biosimilar version of AbbVie’s Humira (adalimumab), which is the world’s biggest drug blockbuster. Now, the biopharma has struck a marketing partnership for adalimumab--and 8 other biosimilars--with Daiichi Sankyo in Japan.

Boehringer strikes deal to develop protein-degrading cancer drugs

Thursday, July 14, 2016

Boehringer Ingelheim has teamed up with the University of Dundee to develop proteolysis targeting chimeric molecules (PROTACs), a new class of drugs designed to degrade proteins. The idea is to leverage the cell’s own disposal system to eliminate proteins involved in the development of diseases including cancer.

This week's sponsor is Validic.

eBook | Exploring Digital Health Technologies: The Devices and Data Being Used in Trials Today

Digital health tech is improving clinical trial processes, streamlining timelines, and enabling remote monitoring. But, these advancements can make it hard to stay current on the devices available, and how to best use them in clinical trials. Download today to learn how to stay ahead of the technological curve.